PixarBio Corporation Builds Regulatory Team Adding Steven Chartier, as Vice President of Regulatory Affairs, to Lead Non-Opiate, Non-Addictive Pain Treatment through the US FDA and European Regulatory Bodies

CAMBRIDGE, Mass.--()--PixarBio Corporation announced today the appointment of Steven Chartier as V.P. of Regulatory Affairs. He will report to Frank Reynolds, the company’s Chief Executive Officer. Steve is another important piece to the company’s growing infrastructure, in maintaining momentum toward multiple FDA approvals of non-opiate and non-addictive pain treatments in early 2018.

Steven will oversee all facets of PixarBio Corporation’s Regulatory Affairs, providing oversight for all U.S. and international regulatory matters, including filings and interactions with regulatory authorities.

Prior to joining PixarBio Corporation, Steven worked for eight years at Infraredx, Inc. managing the company’s Regulatory, Quality, Manufacturing, and Clinical departments. From 1998-2007, he led the Regulatory, Quality, and Preclinical development programs at Nucryst Pharmaceuticals. He also worked in Program Management and Laboratory Research at Biogen IDEC, Beth Israel Deaconess Medical Center, and Dana Farber Cancer Institute.

Steven has over 20 years industry experience developing regulatory strategies that have resulted in thirty-one regulatory submissions and approvals of novel technologies worldwide. Over this period, he has significantly contributed to bringing novel drugs and devices to market in the areas of Oncology, Wound Care, Autoimmune and Cardiovascular diseases. Steven holds a BA in Psychology from Saint Anselm College in New Hampshire, and earned his RAC certification from Regulatory Affairs Professional Society.

"As we prepare for clinical studies for multiple pain indications, Steve will lead more than 20+ applications to the US FDA and to European bodies for pain, epilepsy and spinal cord injury products. Steve will expand PixarBio Regulatory strategy to leverage our dominant patent position around the NeuroRelease platform. Market and societal demand for non-addictive, non-opiate pain treatment is outperforming the market," said PixarBio Corporation CEO Frank Reynolds.

About PixarBio Corporation

Cofounded by Frank Reynolds, MIT’s Robert S. Langer, Katrin Holzhaus, and Dr. Jason Criscione, PixarBio is focused on researching and developing targeted drug and cell delivery systems to treat pain, epilepsy, Parkinson’s disease, and spinal cord injury. For more information visit www.pixarbio.com.

Contacts

PixarBio Corporation
Glenn Reiser
617-803-8838
Investor Relations
investorrelations@pixarbio.com

Contacts

PixarBio Corporation
Glenn Reiser
617-803-8838
Investor Relations
investorrelations@pixarbio.com